Lipocine Inc. (LPCN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Lipocine Inc. (LPCN) is down 71.5% since the beginning of the year. At $2 per share, LPCN is trading 81.5% below its 52-week high of $12. Investors who bought $1,000 worth of LPCN shares 5 years ago would now be looking at an investment worth $99.

Lipocine Inc. (LPCN) has returned -71.48% so far this year and -30.61% over the past 12 months. Over the last ten years, LPCN has returned -32.52% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Oct 22, 2013, LPCN's average daily return is +0.04%, while the average monthly return is +0.67%. At this rate, an investment would double in approximately 8.7 years.

Historically, 47% of months were positive and 53% were negative. The best month was Dec 2025 with a return of +133.4%, while the worst month was Nov 2019 at -83.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, LPCN closed higher 45% of trading days. The best single day was Feb 24, 2020 with a return of +67.0%, while the worst single day was Apr 2, 2026 at -77.8%.

Lipocine Inc. has an annualized alpha of 0.70%, beta of 0.69, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 22, 2013.

• This stock participated in 64.85% of S&P 500 Index downside but only -66.58% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.69 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LPCN ranks 39 for risk / return — below 39% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lipocine Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lipocine Inc. was 99.38%, occurring on Apr 6, 2026. The portfolio has not yet recovered.

The current Lipocine Inc. drawdown is 99.27%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lipocine Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lipocine Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.